21st International Congress » Drug-Induced Movement Disorders

1:45pm-3:15pm

Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Efficacy, Safety, and Tolerability of Fixed-Dose Deutetrabenazine for the Treatment of Tardive Dyskinesia

K. Anderson, D. Stamler, M. Davis, S. Factor, R. Hauser, J. Isojärvi, J. Jimenez-Shahed, W. Ondo, H. Fernandez (Washington, DC, USA)

1:45pm-3:15pm

Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Improvements in Clinical Global Impression of Change (CGIC) with Deutetrabenazine Treatment in Tardive Dyskinesia (TD)

J. Jimenez-Shahed, H. Fernandez, R. Hauser, M. Davis, S. Factor, J. Isojärvi, W. Ondo, D. Stamler, K. Anderson (Houston, TX, USA)

1:45pm-3:15pm

An MCID for AIMS Dyskinesia Total Score Change in Subjects with Tardive Dyskinesia

M. Stacy, R. Kurlan, J. Burke, S. Siegert, G. Liang, C. O'Brien (Durham, NC, USA)

1:45pm-3:15pm

An Unusual Cause of Rhabdomyolysis in Parkinson’s disease

Y. Pitakpatapee, C. Satukijchai, P. Srivanitchapoom (Bangkok, Thailand)

1:45pm-3:15pm

D2 receptor mediated DARPP32/PP1α signaling is responsible for cadmium induced Parkinson’s like behavioral alterations in rats

R. Gupta, R. Shukla, V. Khanna (Luckno, India)

1:45pm-3:15pm

Deutetrabenazine is Associated with an Improvement in Involuntary Movements in Patients With Tardive Dyskinesia as Seen by the High Proportion of Responders to Deutetrabenazine Treatment in the AIM-TD Study

J. Jimenez-Shahed, H. Fernandez, D. Stamler, M. Davis, S. Factor, R. Hauser, J. Isojärvi, W. Ondo, K. Anderson (Houston, TX, USA)

1:45pm-3:15pm

Deutetrabenazine Treatment Response by Concomitant Dopamine-Receptor Antagonists in the Phase III, Randomized, Double-Blind, Placebo-Controlled AIM-TD Trial in Tardive Dyskinesia

J. Jimenez-Shahed, H. Fernandez, D. Stamler, M. Davis, S. Factor, R. Hauser, J. Isojärvi, W. Ondo, K. Anderson (Houston, TX, USA)

1:45pm-3:15pm

Dopamine Agonists and Postural Disorders in Parkinson’s disease

L. Ameghino, V. Bruno, M. Merello (Buenos Aires, Argentina)

1:45pm-3:15pm

Drug-induced movement disorders: not a typical problem

A. Vives-Rodriguez, A. Patel (New Haven, CT, USA)

1:45pm-3:15pm

Effect of Deutetrabenazine by Body Region Score of the Abnormal Involuntary Movement Scale in Tardive Dyskinesia: ARM-TD and AIM-TD Studies

H. Fernandez, D. Stamler, M. Davis, S. Factor, R. Hauser, J. Isojärvi, L. Jarskog, J. Jimenez-Shahed, R. Kumar, S. Ochudlo, W. Ondo, K. Anderson (Cleveland, OH, USA)

1:45pm-3:15pm

Effect of Deutetrabenazine on QTcF Interval in the AIM-TD Study: a 12-Week, Phase III, Randomized, Double-Blind, Placebo-Controlled Study

K. Anderson, D. Stamler, M. Davis, S. Factor, R. Hauser, J. Isojärvi, L. Jarskog, J. Jimenez-Shahed, R. Kumar, S. Ochudlo, W. Ondo, H. Fernandez (Washington, DC, USA)

1:45pm-3:15pm

Effect of Deutetrabenazine on Quality of Life in Patients With Tardive Dyskinesia in AIM-TD, a 12-Week Double-Blind, Placebo-Controlled Study

S. Factor, K. Anderson, D. Stamler, M. Davis, R. Hauser, J. Isojärvi, L. Jarskog, J. Jimenez-Shahed, R. Kumar, S. Ochudlo, W. Ondo, H. Fernandez (Atlanta, GA, USA)

1:45pm-3:15pm

Effects of the administration of levodopa on postural control under visual tasks

C. Bonnet, A. Delval, L. Defebvre (Lille, France)

1:45pm-3:15pm

Estimation of Tardive Dyskinesia Incidence and Prevalence in the United States

A. Dhir, T. Schilling, V. Abler, R. Potluri, B. Carroll (New York, NY, USA)

1:45pm-3:15pm

Evaluation of Patient-Reported Outcomes in Tardive Dyskinesia Patients With Underlying Psychotic and Mood Disorders in the ARM-TD and AIM-TD Trials

H. Fernandez, D. Stamler, M. Davis, S. Factor, R. Hauser, J. Isojärvi, L. Jarskog, J. Jimenez-Shahed, R. Kumar, S. Ochudlo, W. Ondo, K. Anderson (Cleveland, OH, USA)

1:45pm-3:15pm

Healthcare Utilization and Costs for Patients With Tardive Dyskinesia

B. Carroll, T. Park, D. Irwin, S. Gandhi (Frazer, PA, USA)

1:45pm-3:15pm

Imbalance between dopaminergic and cholinergic neurotransmission following rotenone administration suggestive of Parkinson’s-like symptoms in male rats

S. Madiha, S. Haider (Karachi, Pakistan)

1:45pm-3:15pm

Improvements in Clinical Global Impression of Change With Deutetrabenazine Treatment in Tardive Dyskinesia From the ARM-TD and AIM-TD Studies

H. Fernandez, D. Stamler, M. Davis, S. Factor, R. Hauser, J. Isojärvi, L. Jarskog, J. Jimenez-Shahed, R. Kumar, S. Ochudlo, W. Ondo, K. Anderson (Cleveland, OH, USA)

1:45pm-3:15pm

Laryngeal Tardive Dyskinesia in a Patient treated with Haldol

R. Joseph, F. Amjad (Columbus, OH, USA)

1:45pm-3:15pm

Long-Term Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia: Results From an Open-Label, Long-Term Study

K. Anderson, D. Stamler, M. Davis, S. Factor, R. Hauser, J. Isojärvi, L. Jarskog, J. Jimenez-Shahed, R. Kumar, S. Ochudlo, W. Ondo, H. Fernandez (Washington, DC, USA)

1:45pm-3:15pm

Low Incidence of Extrapyramidal Symptoms in Subjects with Tardive Dyskinesia Receiving Long-Term Valbenazine (NBI-98854) Treatment

S. Lessig, R. Kurlan, S. Factor, J. Burke, C. Wright, R. Jimenez, G. Liang (La Jolla, CA, USA)

1:45pm-3:15pm

Motor dysfunctions in rats following repeated exposure to stress on the neurotoxicity of lambda-cyhalothrin

R. Shukla, R. Gupta, A. Pant, V. Khanna (Lucknow, India)

1:45pm-3:15pm

Off-Target Implications of Nurr1 Agonist Therapy in Parkinson’s disease

K. Steece-Collier, T. Collier, J. Stancati, C. Kemp, B. Daley, C. Sortwell (Grand Rapids, MI, USA)

1:45pm-3:15pm

Prevalence of Parkinson’s disease and Drug-induced Parkinsonism from National Health Insurance Service Claims Data (NHISCD)

H.-I. MA, S. Jang, J.-s. Kim, S.J. Chung, J.S. Baik, Y.J. Kim (Anyang, Republic of Korea)

1:45pm-3:15pm

Prominent extensor truncal and cervical dystonia induced by mirtazapine

W.T. Yoon (Seoul, Republic of Korea)

1:45pm-3:15pm

Reversible progressive supranuclear palsy-mimic induced by risperidone

H.J. Kim, J.H. Lee (Seoul, Republic of Korea)

1:45pm-3:15pm

Risk of Parkinson’s disease in zolpidem user: A systematic review and meta-analysis

S. Hussain, A.K. Najmi, D. Anil (New Delhi, India)

1:45pm-3:15pm

Substantia nigra hyperechogenicity in male methamphetamine users

G. Todd, V. Pearson-Dennett, B. Collie, J. White (Adelaide, Australia)

1:45pm-3:15pm

Tacrolimus induced parkinsonism presenting as freezing of gait and speech

V. Paramanandam, H. DS, P.C. N (Chennai, India)

1:45pm-3:15pm

Tardive Dyskinesia by Body Region in Subjects with Schizophrenia/Schizoaffective Disorder or Mood Disorder: Findings from the KINECT 3 Study

S. Factor, M. Stacy, J. Burke, C. Yonan, H. Le, G. Liang (Atlanta, GA, USA)

1:45pm-3:15pm

Tardive syndromes induced by coadministration of tramadol and sertralin

H. Sarac, N. Bozina, N. Henigsberg, L. Bagaric-Krakan (Zagreb, Croatia)

1:45pm-3:15pm

Transcranial sonography in the prognosis of drug-induced parkinsonism

Y.-S. Oh, D.-Y. Kwon (Seoul, Republic of Korea)